Evaluating the Impact of Stopping Chronic Therapies after Modulator Drug Therapy in Cystic Fibrosis: The SIMPLIFY Clinical Trial Study Design

The care for individuals with cystic fibrosis (CF) with at least one F508del mutation will greatly change as a result of the unparalleled clinical benefits observed with the new triple-combination CFTR (CF transmembrane regulator)–modulator therapy elexacaftor/tezacaftor/ivacaftor (ETI). Incorporati...

Descripción completa

Detalles Bibliográficos
Autores principales: Mayer-Hamblett, Nicole, Nichols, David P., Odem-Davis, Katherine, Riekert, Kristin A., Sawicki, Greg S., Donaldson, Scott H., Ratjen, Felix, Konstan, Michael W., Simon, Noah, Rosenbluth, Daniel B., Retsch-Bogart, George, Clancy, John P., VanDalfsen, Jill M., Buckingham, Rachael, Gifford, Alex H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Thoracic Society 2021
Materias:
Clinical Study Design
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8513667/
https://www.ncbi.nlm.nih.gov/pubmed/33465316
http://dx.doi.org/10.1513/AnnalsATS.202010-1336SD

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8513667/
https://www.ncbi.nlm.nih.gov/pubmed/33465316
http://dx.doi.org/10.1513/AnnalsATS.202010-1336SD

Ejemplares similares